These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34869007)

  • 1. Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection.
    Chiu ST; Cheng YT; Pu YS; Lu YC; Hong JH; Chung SD; Chiang CH; Huang CY
    Front Oncol; 2021; 11():772182. PubMed ID: 34869007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
    Ferro M; Crocetto F; La Civita E; Fiorenza M; Jannuzzi G; Carbone G; Sirica R; Sicignano E; Pagano G; Imbimbo C; Terracciano D
    Prostate; 2024 Sep; 84(12):1157-1164. PubMed ID: 38798011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study.
    Wu B; Shao Y; Lin X; Hasi C; Jia W; Wang D; Cao X
    Transl Androl Urol; 2023 Mar; 12(3):425-432. PubMed ID: 37032752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer.
    Boo Y; Chung JH; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Song W
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
    Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
    Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of the prostate health index density and multiparametric magnetic resonance imaging in diagnosing clinically significant prostate cancer.
    Chen Y; Xu D; Ruan M; Li H; Lin G; Song G
    Investig Clin Urol; 2023 Jul; 64(4):363-372. PubMed ID: 37417561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection.
    Chen H; Qian Y; Wu Y; Shi B; Zhou J; Qu F; Gu Z; Ding J; Yu Y
    Front Oncol; 2022; 12():864111. PubMed ID: 35463344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Value of the Prostate Health Index and Derived Indexes in the Diagnosis of Prostate Cancer with PI-RADS-3 Lesions.
    Cui Y; Zhao J; Sun Y
    Urol Int; 2023; 107(10-12):959-964. PubMed ID: 38011845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?
    Garrido MM; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
    Clin Chim Acta; 2021 Sep; 520():133-138. PubMed ID: 34097882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions.
    Lee CU; Lee SM; Chung JH; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Song W
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate health index density aids the diagnosis of prostate cancer detected using magnetic resonance imaging targeted prostate biopsy in Taiwanese multicenter study.
    Chang CH; Yu PH; Hsieh PF; Hong JH; Chiang CH; Cheng HM; Wu HC; Huang CY; Lin TP
    J Chin Med Assoc; 2024 Jul; 87(7):678-685. PubMed ID: 38829960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
    Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
    J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection.
    Barisiene M; Bakavicius A; Stanciute D; Jurkeviciene J; Zelvys A; Ulys A; Vitkus D; Jankevicius F
    Biomed Res Int; 2020; 2020():9872146. PubMed ID: 32775459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center.
    Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
    Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of PHI and PHID in the detection of intermediate- and high-risk prostate cancer.
    Filella X; Foj L; Wijngaard R; Luque P
    Clin Chim Acta; 2022 Jun; 531():277-282. PubMed ID: 35483440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
    Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
    BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Role of Morphological Parameters in the Prostate Transition Zone in PHI-Based Predictive Models for Detecting Gray Zone Prostate Cancer.
    Qian YH; Shi YT; Sheng XJ; Liao HH; Chen HJ; Shi BW; Yu YJ
    Clin Med Insights Oncol; 2023; 17():11795549231201122. PubMed ID: 37869472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.